Dr. Barry Dworkin

Merits of new cholesterol-lowering drug overstated in some media reporting

Health Headlines Commentary for March 20, 2017

Source:

Cholesterol drug prevents heart attacks — but costs $14K a year

Reference:

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Related posts:

  1. New class of cholesterol-lowering study drug may help reduce risk of heart disease but be careful of how the data is presented
  2. Press release of new heart disease risk test does not provide accuracy and disease-prevention outcome data
  3. Study bias against methadone distribution clinics blinds them to the deficiencies of mental health cares services in Ontario
  4. DNA testing to determine best choice of antidepressant not yet ready for clinical use. Data to be released in 2019 regarding test’s efficacy and patient outcomes.